October 19th 2025
Data from IDeate-Lung01 reveal a disease control rate exceeding 90% with infinatamab deruxtecan.
October 18th 2025
Data from DeLLphi-304 support the use of tarlatamab as a standard of care for all patients with second-line small cell lung cancer.
Tarlatamab plus chemo/IO showed a 71% objective response rate and promising safety for patients with ES-SCLC in the DeLLphi-303 study.
October 4th 2025
Those with limited-stage small cell lung cancer who had elevated ProGRP levels at baseline had worse OS and PFS outcomes vs those with normalized levels.
October 3rd 2025
Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.
FDA Approves Lurbinectedin/Atezolizumab Maintenance in ES-SCLC
Data from the phase 3 IMforte trial support the FDA approval of maintenance lurbinectedin plus atezolizumab in extensive-stage small cell lung cancer.
Tarlatamab Requires Strategic Toxicity Monitoring and Management in ES-SCLC
A real-world, retrospective analysis showed that CRS and ICANS occurred in 48% and 16% of patients with ES-SCLC who were treated with tarlatamab.
Exploring T-Cell Engager Use in Chemotherapy-Resistant ES-SCLC
Biomarker research may better elucidate clinical benefit and identify mechanisms of resistance with tarlatamab in extensive-stage small cell lung cancer.
Understanding “Paradigm-Changing” Events in Small Cell Lung Cancer Care
The frontline treatment algorithm in SCLC is poised to look “radically different” in the upcoming years, according to Anne Chiang, MD, PhD.
Thoracic Consolidation Plus SBRT to Cranial Mets May Improve OS in ES-SCLC
In patients with ES-ECLC treated with chemotherapy and immunotherapy, stereotactic body radiation therapy did not significantly improve overall survival.
Toripalimab Consolidation Improves Survival in Limited-Stage SCLC
In patients with LS-SCLC who were ineligible for a prophylactic cranial irradiation, toripalimab appeared to decrease the progression of brain metastases.
Niraparib Triplet Shows PFS Benefit vs Atezolizumab as ES-SCLC Maintenance
Future biomarker analysis will include correlation of efficacy with SLFN11 expression and with markers of DNA damage repair.
Cisplatin/Carboplatin Plus Etoposide Yield Similar Real-World Efficacy in ES-SCLC
Cisplatin/etoposide and carboplatin/etoposide achieved median OS of 8.8 months and 7.8 months, respectively, in those with extensive-stage small cell lung cancer.
I-DXd Shows “Impressive” Responses in Extensive-Stage SCLC
Data from the IDeate-Lung01 trial support the potential role that ifinatamab deruxtecan may play in the management of extensive-stage small cell lung cancer.
Lurbinectedin Yields Responses in Various ES-SCLC Subgroups
Lurbinectedin achieved an ORR of 27% in all patients with extensive-stage small cell lung cancer in the phase 4 Jazz Emerge 402 study.
Surufatinib Combo Displays Promising Efficacy in Frontline ES-SCLC
All efficacy-evaluable patients with ES-SCLC treated with surufatinib, durvalumab, etoposide, and chemotherapy responded to treatment.
Vobramitamab Duocarmazine Does Not Achieve Responses in R/R ES-SCLC
After failing to record any objective responses in 9 patients with relapsed/refractory ES-SCLC, the phase 2 trial was terminated early.
Tarlatamab Remains Safe and Effective in Extensive-Stage SCLC
Results from the DeLLphi-303 trial showed sustained efficacy and safety with tarlatamab plus anti–PD-1 treatment for patients with extensive-stage SCLC.
Durvalumab Combo Enhances OS vs Chemo Alone in Treatment-Naive ES-SCLC
Rates of grade 3 or 4 AEs with durvalumab were similar across subgroups, with serious AEs more frequent in patients 70 years or older with ES-SCLC.
ABBV-706 Demonstrates Tumor Shrinkage, Tolerability in Pretreated R/R SCLC
The confirmed overall response rate with ABB-706 was 77% in patients with relapsed/refractory small cell lung cancer who received 2 prior lines of therapy.
Lung Oncologists Take to Social Media to Highlight Impactful WCLC Abstracts
Leveraging #WCLC25, lung oncologists spoke about the presentations they’re most looking forward to at the upcoming conference.
Atezolizumab Plus Chemo Is Safe, Efficacious in Broader ES-SCLC Population
The median overall survival with atezolizumab plus carboplatin and etoposide was 10.6 months in patients with extensive-stage small cell lung cancer.
Serplulimab Plus Chemotherapy Improves OS and PFS in Older ES-SCLC Populations
The biomarker NLR may not be suitable for prognosis prediction in older patients with small cell lung cancer, according to findings from this real-world study.
Consolidative Thoracic Radiotherapy Displays Safety, Efficacy in ES-SCLC
No treatment-related deaths were observed with radiotherapy for extensive-stage small cell lung cancer, and most adverse effects were grade 1 or 2.
Nivolumab Plus Chemo Improved OS and PFS in Frontline ES-SCLC
The median PFS and OS were 5.5 months and 11.2 months, respectively, with nivolumab plus carboplatin/cisplatin and etoposide in patients with small cell lung cancer.
Chemoimmunotherapy Less Safe, Efficacious in Younger ES-SCLC Population
Results from a retrospective study showed that chemoimmunotherapy did not prolong survival vs chemotherapy in a younger ES-SCLC population.
Anlotinib/Irinotecan Shows Promise, Durable Responses in ES-SCLC
Patients with extensive-stage small cell lung cancer experienced a median PFS and OS of 4.5 months and 7.2 months, respectively, with anlotinib plus irinotecan.
NCCN Guidelines Add LEMS Antibody Testing for SCLC
Symptom specificity is now included in updated guidelines for SCLC relating to LEMS, characterized by proximal muscle weakness and autonomic dysfunction.
Outlining Next Steps for Tarlatamab in Early-Line ES-SCLC and Beyond
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
Tarlatamab Provides Clinicians With New Immunologic Option in SCLC
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
Tarlatamab and DLL3 May Open New Opportunities in SCLC Management
The field is just beginning to open the door for cellular therapy in lung cancer and other solid tumors, according to Daniel R. Carrizosa, MD, MS, FACP.
3 Things You Should Know About Evolving Strategies in SCLC: Limited-Stage Advances, Frontline Innovation, and Postplatinum Progress
Explore innovative strategies and emerging therapies transforming small cell lung cancer treatment, enhancing patient outcomes and survival rates.
Real-World Lurbinectedin Exhibits Safety and Modest Efficacy in ES-SCLC
The investigational agent showed particularly strong efficacy in an ES-SCLC subgroup, with a chemotherapy-free interval of 90 or more days.
Frontline LDRT Plus Atezolizumab Combo Shows Efficacy in ES-SCLC
The confirmed objective response rate among 56 patients with extensive-stage small cell lung cancer was 87.5%, all of whom experienced partial responses.
SRS Lessens Rate of Neurologic Death vs WBRT in SCLC and Brain Metastases
Results from a phase 2 study showed a median OS of 10.2 months in all patients with small cell lung cancer who received stereotactic radiation therapy.